BioSpace News Archive

Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now been approved in New Zealand.

Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose.

ANSYS, Inc. (NASDAQ: ANSS) announced today that the Company expects to release its fourth quarter and FY 2022 earnings on Wednesday, February 22, 2023, after the market closes.

Liminal BioSciences Inc., announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023.

EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which demonstrated that RRx-001 protects against severe oral mucositis in patients receiving radiation and chemotherapy for head and neck cancer.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Mabwell, an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. about 9MW3011.

XNK Therapeutics AB announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer, effective immediately.

Immunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test.